Rising Infectious Disease Incidences Drive Growth In The Multivalent Vaccine Market Emerges as a Core Driver of the Multivalent Vaccines Market in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Multivalent Vaccines Market Through 2025?
In the past few years, the market size of multivalent vaccines has experienced substantial growth. A forecast suggests that it will expand from $8.37 billion in 2024 to $9.12 billion in 2025, indicating a compound annual growth rate (CAGR) of 8.9%. Factors contributing to this significant expansion during the historic period comprise of growing public awareness about vaccination, enhanced governmental support, escalating demand for multivalent vaccines designed for children, a boost in funding dedicated to vaccine research, and an overall increased demand for multivalent vaccines.

What's the Projected Size of the Global Multivalent Vaccines Market by 2029?
Expectations are high for robust expansion in the multivalent vaccines market in the coming years, with projections putting it at a value of $13.05 billion by 2029, growing at a compound annual growth rate (CAGR) of 9.4%. Factors contributing to this growth in the projected period include a surge in infectious diseases, a growing elderly population, increased investment by both public and private entities, heightened focus on vaccination safety and efficacy, and increased emphasis on therapeutic vaccines. The forecast period is likely to see a greater focus on combination vaccines, the adoption of digital health technologies, advancements in mRNA technology, the creation of personalized vaccines, and heightened research activities.

View the full report here:
https://www.thebusinessresearchcompany.com/report/multivalent-vaccines-global-market-report

Top Growth Drivers in the Multivalent Vaccines Industry: What's Accelerating the Market?
The increasing cases of infectious diseases are anticipated to boost the development of the multivalent vaccines market. Infectious diseases, spurred by bacteria, viruses, fungi, or parasites, convey through direct interaction, contaminated surfaces, or through air or water and the severity may vary from mild to extreme. The swift spread of infectious diseases facilitated by global travel enables pathogens to cross borders rapidly and infect novel populations. Multivalent vaccines offer extensive protection against infectious diseases by targeting multiple strains of pathogens in one dose, thereby eliminating the need for separate inoculations. This wide coverage enhances herd immunity, reduces disease prevalence, thereby improving public health. For example, TravelHealthPro, a UK-orientated website backed by the UK Health Security Agency, reported in its April 2024 publication that there were 2,004 malaria cases in the UK during 2023, representing an increase compared to the 1,369 imported cases reported in 2022. Hence, the escalating occurrences of infectious diseases are propelling the growth of the multivalent vaccines market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19120&type=smp

What Are the Key Trends Driving Multivalent Vaccines Market Growth?
Major firms within the multivalent vaccines market are concentrating their efforts on the creation of cutting-edge pentavalent vaccines, with a goal of boosting public health outcomes through a wider protection offered by a single dose. Pentavalent vaccines, which are a type of multivalent vaccine, provide immunity against five different pathogens or strains. This consolidation of protective measures into one vaccine simplifies immunization timetables and boosts vaccine reach. For example, in December 2023, Panacea Biotec Ltd., a biotech corporation based in India, unveiled EasyFourPol. This product holds the distinction of being the world's first fully liquid vaccine that safeguards against five severe diseases including diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae Type B infections. This ready-to-administer combined vaccine takes away the need for healthcare staff to prepare the vaccine, thereby making the vaccination procedure more efficient. It gives the same protective benefits as individual antigen vaccines, decreases the clinic visits required for children, and brings down the total cost of immunizations. Moreover, it bolsters vaccination productivity and reduces environmental damage by lessening the demand for vials, syringes, and packaging.

What Are the Main Segments in the Multivalent Vaccines Market?
The multivalent vaccines market covered in this report is segmented -

1) By Type: Conjugate Vaccines, Inactivated And Subunit Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Recombinant Vaccines
2) By Disease: Influenza, Pneumonia, Hepatitis, Meningitis, Rotavirus
3) By Route Of Administration: Oral, Injectable
4) By Age Group: Pediatrics, Adults, Geriatrics
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:
1) By Conjugate Vaccines: Polysaccharide Conjugate Vaccines, Protein Conjugate Vaccines
2) By Inactivated And Subunit Vaccines: Inactivated Whole Virus Vaccines, Subunit Protein Vaccines, Virus-Like Particle Vaccines
3) By Live Attenuated Vaccines: Live Attenuated Bacterial Vaccines, Live Attenuated Viral Vaccines
4) By Toxoid Vaccines: Diphtheria Toxoid Vaccines, Tetanus Toxoid Vaccines
5) By Recombinant Vaccines: Recombinant Protein Vaccines, Recombinant DNA Vaccines

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=19120&type=smp

Which Top Companies are Driving Growth in the Multivalent Vaccines Market?
Major companies operating in the multivalent vaccines market are Pfizer Inc., Merck & Co. Inc., Sanofi SA, AstraZeneca plc, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Moderna Inc., BioNTech SE, Zydus Lifesciences Limited, CSL Seqirus, Sinovac Biotech Ltd., GC Biopharma corp., Emergent BioSolutions Inc., Serum Institute of India Pvt. Ltd., Indian Immunologicals Ltd., Bavarian Nordic, Panacea Biotec Ltd., WestVac Biopharma Co. Ltd., VBI Vaccines Inc.

Which Regions Will Dominate the Multivalent Vaccines Market Through 2029?
North America was the largest region in the multivalent vaccines market in 2024. The regions covered in the multivalent vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19120

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795,
Asia +44 7882 955267 & +91 8897263534,
Europe +44 7882 955267
Email: saumyas@tbrc.info
The Business Research Company - www.thebusinessresearchcompany.com

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.